Background {#Sec1}
==========

Lung cancer is one of the most common malignant tumors worldwide and the first leading cause of cancer-related mortality in China \[[@CR1], [@CR2]\]. According to World Health Organization, lung cancer is divided into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which NSCLC accounts for almost 85% of lung cancer cases \[[@CR3]\]. Epidemiological studies have identified several risk factors for lung cancer, such as tobacco smoking, atmospheric pollution and occupational environment challenge \[[@CR4]\]. However, many individuals who have been exposed to these risk factors do not get lung cancer during lifetime, so genetic factor is likely play an important role.

The initiation and progression of cancer are closely linked to inflammation and angiogenesis \[[@CR5], [@CR6]\]. As one of potent mediators of inflammation, the tumor necrosis factor (TNF) family plays an important role in the process of immunoregulation and further contributes to cancer development \[[@CR7]\]. Tumor necrosis factor superfamily 15 (*TNFSF15*), also known as vascular endothelial growth inhibitor (*VEGI*), belongs to the *TNF* ligand family, which negatively regulates angiogenesis \[[@CR8]\]. By stimulating T cell, TNFSF15 is involved in the modulation of inflammation \[[@CR9], [@CR10]\]. Studies have shown that over-expression of TNFSF15 inhibits tumor growth in various cancers whereas reduced expression of TNFSF15 is associated with poor prognosis in cancer patients \[[@CR11]--[@CR15]\].

Single nucleotide polymorphisms (SNPs) in regulatory region of a gene can influence the gene expression and further contribute to the development of various cancers \[[@CR16]--[@CR19]\]. In our previous study, we identified two SNPs (−638A \> G and -358 T \> C) in the *TNFSF15* promoter by direct sequencing, and found that -358 T \> C variant changed the transcriptional activity of *TNFSF15* and was significantly associated with the susceptibility to gastric adenocarcinoma \[[@CR20]\]. In the present study, we tested if these two variants in the *TNFSF15* promoter region contributed to the risk of developing lung cancer by performing a case-control study in a Chinese population.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This case-control study consisted of 209 SCLC patients, 340 NSCLC patients and 460 healthy controls (Table [1](#Tab1){ref-type="table"}). The 549 cases were collected from Tangshan Gongren Hospital and Tangshan Renmin Hospital affiliated to North China University of Science and Technology in China from 2012 to 2016. None of the patients were treated with any radiotherapy or chemotherapy before blood sampling. All subjects were unrelated ethnic Han Chinese. Control individuals without a history of any cancer were recruited from the same region and frequency-matched to cases according to gender and age. This study was approved by Institutional Review Board of North China University of Science and Technology, and written informed consents were obtained from all participants of their own free will.Table 1Frequency distribution of select characteristicsVariablesNSCLCSCLCCase (*n* = 340)Controls(*n* = 460)*P* value^*\**^Case (*n* = 209)Controls(n = 460)*P* value^*\**^No(%)No(%)No(%)No(%)Gender0.3010.862 Male23769.733673.015473.733673.0 Female10330.312427.05526.312427.0Age0.1390.151 \<6018755.027760.213866.027760.2  ≥ 6015345.018339.87134.018339.8Range27--8418--8430--9218--84Median5856.25556.2Smoking status0.2520.431 Non-smoker18755.023350.79947.823350.7 Smoker15345.022749.311052.222749.3Pack year of smoking\< 0.001\< 0.001 \<305938.615367.43733.715367.4  ≥ 309461.47432.67366.47432.6^\*^Two-sided χ2 test

*TNFSF15* genotyping {#Sec4}
--------------------

Genomic DNA was extracted from peripheral blood from all participants using TIANamp Blood DNA Kit (TIANGEN, Beijing, China), according to the manufacturer's instructions. PCR-restriction fragment length polymorphism (PCR-RFLP) analysis were applied for *TNFSF15* genotyping. The PCR primer pairs for −638A \> G (rs7848647) were 5′- AGT CAC CTC GAT CTG TGG CCTC-3′ and 5′-AAT CAC GGC TTG GAG TTG TAA CCTC-3′. The target DNA fragment containing − 358 T \> C (rs6478109) was amplified with primer pairs, − 358 -PF (5′-AAA TGT GAT TTC CGT TTC CCCA-3′) and − 358 -PR (5′- AAT ATA CCT GTT CCC TGC ACTG -3′). Briefly, PCR was performed using 6 μL reaction mixture containing 10 ng DNA, 0.1 μM each primer, and 1 × Taq PCR StarMix with loading dye (Genstar, Beijing, China).The PCR thermal cycling condition consists of an initial denaturation step at 94 °C for 3 min, followed by 30 cycles of 94 °C for 40 s, 58 °C for 30 s and 72 °C for 15 s, and then a final extension step at 72 °C for 3 min. PCR products for *TNFSF15*--638A \> G (114 bp) and -358 T \> C (123 bp) were digested by Rsa *I* and Bcc *I* (New England BioLabs, Inc., Beverly, USA) and separated on 3% agarose gel. The genotypes revealed by PCR-RFLP were further confirmed by DNA sequencing (Fig. [1](#Fig1){ref-type="fig"}). To ensure the quality control, approximately10% of the samples were randomly selected for re-genotyping and all results were in 100% concordance.Fig. 1Sequence analyses of the *TNFSF15* promoter region reveal 2 SNPs located at nucleotides **a** − 638 A \> G and **b** − 358 T \> C. The arrows localize the base changes at the nucleotide positions

Statistical analysis {#Sec5}
--------------------

Quanto program was used to calculate the power of the sample size for this case-control study. The power estimation was performed, which indicated that our sample size is sufficient for the case-control study. Differences of basic characteristics in cases and control subjects were compared using the χ^2^ test. Pearson goodness-of-fit χ^2^ test was performed to test whether the distribution of genotypes in the control group was in accordance with Hardy-Weinberg Equilibrium (HWE). Odd ratios (ORs) and 95% Confidence interval (CI) were calculated by unconditional logistic regression model to evaluate the association of *TNFSF15* genetic variations with the susceptibility to lung cancer. The smoking status of pack-years was determined as an indicator of the cumulative cigarette dose level (pack-years cigarettes per day/20 × years smoked). Light and heavy smokers were categorized by using 30 as the cut-off point \[[@CR21]\]. Older and younger subjects were sub-grouped by using 60 as the cut-off point (<https://www.who.int>). All statistical calculations were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL).

Results {#Sec6}
=======

Demographic and clinical characteristics of lung cancer cases and controls {#Sec7}
--------------------------------------------------------------------------

Demographic and clinical characteristics of lung cancer cases and controls are shown in Table [1](#Tab1){ref-type="table"}. There was no significant difference in gender, age and smoking status between NSCLC or SCLC cases and healthy controls (*P* \> 0.05). In terms of the amount of smoking, the significant difference was showed between lung cancer group and control group (*P* \< 0.001 for NSCLC and *P* \< 0.001 for SCLC). The proportion of heavy smokers in SCLC and NSCLC patients (66.4 and 61.4%) was significantly higher than that in healthy controls (32.6%).

Association of *TNFSF15* variants with the risk of lung cancer {#Sec8}
--------------------------------------------------------------

Tables [2](#Tab2){ref-type="table"} and  [3](#Tab3){ref-type="table"} present the genotypes of *TNFSF15*--638A \> G and -358 T \> C variants in lung cancer patients and controls. Genotype distributions of *TNFSF15*--638A \> G and -358 T \> C in controls were conformed to be in the Hardy-Weinberg equilibrium (HWE) (*P* = 0.32 and *P* = 0.78, respectively). We used unconditional logistic regression to assess the association of *TNFSF15* SNPs with the risk of lung cancer. For the *TNFSF15*--638A \> G polymorphism, we found that GG genotype carriers had a significantly elevated risk for developing SCLC (*OR* = 1.84, *95%CI* = 1.13--2.99), but not for developing NSCLC (*OR* = 1.11, *95%CI* = 0.74--1.67), in comparison to those with AA genotype. For the *TNFSF15* -358 T \> C variant, our data showed that CC genotype and CT genotype were associated with a higher risk of SCLC (*OR* = 2.44, *95%CI* = 1.46--4.06; OR = 2.00, *95%CI* = 1.26--3.19) as compared to TT genotype. However, we did not find that the *TNFSF15* -358 T \> C polymorphism was associated with the susceptibility to NSCLC with an *OR* *(95% CI)* of 1.45 (0.96--2.11) in CT carriers and an *OR (95% CI)* of 1.24 (0.86--1.76) in CC carriers, respectively.Table 2Genotype frequencies of *TNFSF15* polymorphisms and their association with SCLCGenotypePatients(n = 209)Controls(n = 460)OR (95%CI)^a^*P* valueNo(%)No(%)-638 A \> G AA3918.712226.5 AG11253.524052.21.46(0.95--2.23)0.084 GG5827.89821.31.84(1.13--2.99)0.014-358 T \> C TT2913.911625.2 CT11454.523350.72.00(1.26--3.19)0.004 CC6631.611124.12.44(1.46--4.06)0.001^a^Adjusted for age, gender, and smoking statusTable 3Genotype frequencies of *TNFSF15* polymorphisms and their association with NSCLCGenotypePatients(n = 340)Controls(n = 460)*OR* (95%*CI*)^a^*P* valueNo(%)No(%)-638 A \> G AA9026.512226.5 AG17150.324052.20.97(0.69--1.36)0.867 GG7923.29821.31.11(0.74--1.67)0.605-358 T \> C TT7120.911625.2 CT17350.923350.71.24(0.86--1.76)0.248 CC9628.211124.11.45(0.96--2.11)0.074^a^Adjusted for age, gender, and smoking status

Stratification analysis of the *TNFSF15* polymorphism and the risk of SCLC {#Sec9}
--------------------------------------------------------------------------

To evaluate the effect of smoking status and non-modifiable risk factors (age and gender) on the association of *TNFSF15*--638A \> G with the risk of SCLC, we performed stratification analysis (Table [4](#Tab4){ref-type="table"}). When stratified by gender, the *TNFSF15*--638GG genotype was associated with an increased risk of SCLC among males compared with the AA genotype (*OR* = 1.95, 95%*CI* = 1.09--3.45, *P* = 0.023), but not among females. Our data also showed that the risk of SCLC was associated with the −638GG genotype among older subjects with an *OR* (95% *CI*) of 2.93 (1.44--8.68), but not among younger subjects with an *OR* (95% *CI*) of 1.28 (0.71--2.34). However, no effect of the *TNFSF15*--638A \> G variation on the risk of SCLC was found in stratified analysis based on smoking status.Table 4Association of *TNFSF15--*638A \> G polymorphism with SCLC risk stratified by selected variablesVariablesGenotypes (Cases/Controls)GG/AA model\
*OR* (95% *CI*)*P* valueGGAGAAGender Male42/7284/17028/941.95(1.09--3.45)0.023 Female16/2628/7011/281.41(0.54--3.70)0.483Age \<6037/6271/14930/661.28(0.71--2.34)0.407  ≥ 6021/3641/919/562.93(1.44--8.68)0.006Smoking status Non-smoker28/4953/12418/601.79(0.88--3.65)0.107 Smoker30/4959/11621/621.70(0.86--3.38)0.130

We then performed stratification analysis to evaluate the association of *TNFSF15* -358 T \> C genotypes with SCLC (Table [5](#Tab5){ref-type="table"}). Compared with the TT genotype, the CC genotype was associated with a higher risk of SCLC among females (*OR* = 8.42, 95%*CI* = 2.22--31.89, *P* = 0.002), but not among males. Age stratification analysis showed that there was a correlation between the CC genotype and the risk of SCLC (*OR* = 11.04, 95%*CI* = 3.57--34.15, *P* = 0.000) among elders when compared to TT carriers, but not among youngers. In addition, the CC genotype increased the risk of lung cancer among non-smokers (*OR* = 2.54, 95%*CI* = 1.20--5.35, *P* = 0.015) compared with the TT genotype.Table 5Association of *TNFSF15* -358 T \> C polymorphism with SCLC risk stratified by selected variablesVariablesGenotypes (Cases/Controls)CC/TT model\
*OR* (95% *CI*)*P* valueCCCTTTGender Male42/8586/16426/871.66(0.93--2.95)0.086 Female24/2628/693/298.42(2.22--31.89)0.002Age \<6035/7178/14625/601.15(0.62--2.15)0.653  ≥ 6031/4036/874/5611.04(3.57--34.15)\< 0.001Smoking status Non-smoker36/5551/12312/552.54(1.20--5.35)0.015 Smoker30/5663/11017/611.88(0.92--3.84)0.086

Discussion {#Sec10}
==========

Small-cell lung cancer (SCLC) is a deadly tumor with poor prognosis, which originates from high-grade malignant neuroendocrine cells \[[@CR22]\]. Although sensitive to chemotherapy and radiotherapy, SCLC typically recurs rapidly after primary treatment and the five-year survival is only 6% after diagnosis \[[@CR23]\]. Platinum-etoposide doublet has been officially approved for clinical use against SCLC \[[@CR23]\]; however, few improvement has been made in SCLC treatment in past several years. Since SCLC is known as a stubborn cancer, there is an urgent need for the identification of biomarkers that can act as a potential therapeutic target in SCLC.

TNF superfamily members play an important role in cell proliferation, differentiation and apoptosis and are used for clinical treatment, or in clinical trials \[[@CR24], [@CR25]\]. TNFSF15, a member of *TNF* superfamily, is likely to inhibit the growth of tumors by suppressing neovascularization. TNFSF15 inhibits the proliferation of vascular endothelial cells in the G0 and G1 phases of cell cycle, and ultimately inhibits angiogenesis. *TNFSF15* gene encodes three splice variants, namely *VEGI*-174, *VEGI*-251 and *VEGI*-192 depending on the number of amino acids included \[[@CR26]\]. *VEGI*-251, also known as *TL1A* (*TNF*-like molecule 1A), is the longest one of the splice variants. The combination of *TL1A* and *DR3* (Death Receptor 3) activates different signal transduction pathways by inducing *NF-kB* to activate initial T cell \[[@CR10]\] and activating Caspases cascade to promote cell apoptosis \[[@CR27]\]. These processes play an important role in the occurrence and development of tumors.

Till now, a few studies have been carried out to demonstrate the association of *TNFSF15* polymorphisms with the susceptibility to cancer. In our previous study, we found that *TNFSF15*--638A \> G polymorphism was associated with the development of gastric adenocarcinoma \[[@CR20]\]. In another study, authors indicated that *TNFSF15* rs6478106 is related to the risk of breast cancer in Chinese Han population \[[@CR28]\]. In this study, we explored the association of *TNFSF15* variants with the susceptibility to lung cancer and found that -638A \> G and -358 T \> C variants elevated the risk of SCLC, but not of NSCLC. These findings suggested that the *TNFSF15* polymorphisms were involved in the development of various cancer types; however, the specific mechanism is not fully clear. We speculate that the TNFSF15 genetic variation affects the expression of TNFSF15 protein and then controls the downstream signal transduction molecules. These changes affect inflammatory and immune response, and further contribute to the development of cancers. Matijja and Clara found that an intron polymorphism of *TNFSF15* (rs6478108) affected the expression level of *TNFSF15* and increased NOD2-induced signaling and cytokines through caspase-8--induced IL-1 \[[@CR29]\]. In our previous study, we found that the − 358 T \> C polymorphism eliminates a nuclear factor Y (NF-Y) binding site and the -358C containing haplotypes had a significantly decreased reporter gene activity in gastric cells \[[@CR20]\].

Tobacco smoking is recognized as one of the most important risk factors contributing to lung cancer \[[@CR30]\]. Thus, we analyzed the effects of *TNFSF15* variants on SCLC by smoking status. Studies have shown a strong association between tobacco exposure and the development of SCLC \[[@CR31], [@CR32]\]. Cigarette smoke contains many carcinogenic chemicals such as nicotine and carbon monoxide tar. The complexity of cigarette smoke makes the mechanisms of developing lung cancer even more complicated. At least, tobacco smoking potentially alters the tumor immune microenvironment by creating DNA damage and causing inflammatory response \[[@CR33], [@CR34]\]. TNFSF15 is closely related to the inflammatory response. It has been reported that TNFSF15 can directly induce proinflammatory cytokines \[[@CR35]\]. Long-term exposure of DNA to the carcinogens in tobacco smoke will lead to a higher mutation load in SCLC \[[@CR36]\]. Our present data showed that *TNFSF15* -358 T \> C polymorphism was related to SCLC among non-smokers instead of smokers, which needs more studies to explain. After stratified by smoking status, the sample size is not enough to evaluate the risk of this genetic variant with the risk of SCLC.

Age and gender are considered to be risk factors for tumor development and progression \[[@CR37]\]. Our study showed the *TNFSF15*--638GG genotype elevated the risk of SCLC among males and individuals aged 60 years and older. Whether gender is related to the risk of lung cancer is controversial after taking into account smoking \[[@CR38]--[@CR40]\]. Due to the small size of several subgroups, a further larger-scale study needs to be conducted in order to carefully evaluate these findings.

In the future, it is necessary to evaluate the usability of these polymorphisms as a low-cost NSCLC screening tool for predicting individual lung cancer risk.

Conclusion {#Sec11}
==========

Taken together, our results indicated that *TNFSF15* promoter polymorphisms might be involved in the development of SCLC.

NSCLC

:   non-small cell lung cancer

SCLC

:   small cell lung cancer

TNFSF15

:   Tumor necrosis factor superfamily member 15
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